亚宝药业：终止SY-009的临床研究开发工作，并根据会计准则全额计提资产减值准备

Core Points - The company has decided to terminate the clinical research and development of SY-009, a sodium-glucose co-transporter 1 inhibitor intended for the treatment of type 2 diabetes [1] - The total investment in the development of SY-009 amounts to 87.8698 million yuan, with 32.0765 million yuan expensed and 55.7933 million yuan capitalized [1] - The impairment provision will reduce the company's total profit for the year 2025 by 55.7933 million yuan [1]